List view / Grid view
In this exclusive article, Drug Target Review’s Izzy Wood highlights ground-breaking ovarian cancer research, after speaking with Dr Benjamin Neuditschko, from the Institute Krems Bioanalytics at IMC Krems.
A new approach using CAR T-cell therapy is suggested by Swedish researchers as an effective treatment for ovarian cancer.
US researchers found that the severity of muscle wasting from cancer is related to the type, size and location of the tumour, in mice.
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
In a new study, researchers have shared the identification of a new potential target for CAR T cells that inhibits growth in lung and ovarian tumours.
The University at Buffalo has received a $2.3 million grant from the US National Cancer Institute to identify metabolic vulnerabilities of ovarian cancer and to develop potential treatments for the disease.
Researchers have found how ovarian cancer tumours defy immunotherapy, identifying new molecular targets that might boost immune response.
New research has discovered metabolic mechanisms that contribute to how ovarian cancer escapes from immune attack and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
Scientists have uncovered the crucial role of the enzyme NMNAT-2 in ovarian cancers, as well as other biomarkers that could lead to treatments.
A new radiopharmaceutical compound has shown success at treating ovarian cancer in mice and in vitro studies.
A range of imaging and computational techniques were used by researchers to discover the structure of the PH domain of PLEKHA7.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.
Using a mouse model, researchers found that cancer progression led to fewer skeletal muscle ribosomes, likely explaining muscle wasting.
